POLYPEPTIDE THERAPEUTIC SOLUTIONS SOCIEDAD LIMITADA

Their core work

PTS is a Valencia-based biotech SME that designs and synthesizes polypeptide-based polymeric materials for therapeutic and biomedical applications. Their core work sits at the intersection of synthetic polymer chemistry and drug delivery: engineering diblock copolymers, glycopolymers, and self-assembling nanostructures such as polymersomes that can carry and release active compounds in biological environments. In EU consortia, they contribute as specialist chemists — translating complex macromolecular designs into functional materials that industrial or academic partners can test and apply. Their name reflects their identity: polypeptide chemistry is not a side activity but the foundation of everything they do.

What they specialise in

How they've shifted over time

In their first project (PEPTICAPS, 2015–2018), PTS focused on applied polymer processing: designing copolymers as emulsifiers for controlled encapsulation, a problem with direct relevance to pharmaceutical manufacturing. No fundamental biology keywords appear from that period — the work was material design for functional formulation. By 2020 (BIOMOLMACS), the language shifted clearly toward cell-interactive science: glycopolymers, polymersomes, molecular machines functioning inside living cells. This is not just a terminology change — it reflects a move up the complexity ladder, from engineering polymer assemblies for controlled release toward designing materials that interact with and respond to cellular machinery.

PTS is moving from applied polymer formulation toward biomolecular materials that function inside living systems — positioning them for future work in targeted drug delivery, intracellular therapeutics, and synthetic biology-adjacent research.

How they like to work

PTS has always joined consortia as a participant, never as coordinator — a consistent pattern of contributing specialized polymer chemistry expertise rather than managing project-level coordination. Across just two projects they accumulated 20 unique partners in 10 countries, which is a broad network footprint for an SME, suggesting they are valued contributors who get invited into diverse teams. Their participation in an MSCA-ITN (a training network, BIOMOLMACS) alongside a manufacturing-oriented RIA (PEPTICAPS) shows they are comfortable working across project types and consortium cultures.

PTS has built a surprisingly wide network for a two-project SME: 20 unique partners across 10 countries, suggesting active engagement in mid-to-large consortia where their polymer synthesis capability is a sought-after contribution. No repeated partner clusters are visible from the available data, so their network appears genuinely diverse rather than concentrated around one institution.

What sets them apart

PTS occupies a rare niche: a private SME with deep polypeptide synthesis expertise that can operate both in applied manufacturing contexts and in fundamental academic research consortia — most organizations do one or the other. For consortium builders, this flexibility is valuable: PTS can serve as the materials chemistry arm in a drug delivery project, a formulation partner in a food or agrochemical encapsulation project, or a specialist contributor in an MSCA training network. Their SME status also means they bring industrial relevance and exploitation potential that purely academic partners cannot offer.

Highlights from their portfolio

• PEPTICAPS
  Their largest funded project (€482,875) and their founding-era work — designing polypeptide copolymer emulsifiers for safe, controlled encapsulation, directly aligned with their company name and core identity.
• BIOMOLMACS
  Participation in an MSCA Innovative Training Network is unusual for a small SME and signals that PTS is trusted as an industrial training partner in advanced biomolecular materials research, not just a technology supplier.